Fennec Pharmaceuticals Inc. (FENC)
| Market Cap | 253.11M |
| Revenue (ttm) | 21.25M |
| Net Income (ttm) | -16.05M |
| Shares Out | 27.10M |
| EPS (ttm) | -0.60 |
| PE Ratio | n/a |
| Forward PE | 15.20 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 143,207 |
| Open | 9.52 |
| Previous Close | 9.57 |
| Day's Range | 9.18 - 9.68 |
| 52-Week Range | 6.30 - 11.92 |
| Beta | 0.40 |
| Analysts | Strong Buy |
| Price Target | 18.00 (+92.72%) |
| Earnings Date | May 9, 2024 |
About FENC
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is ba... [Read more]
Financial Performance
In 2023, FENC's revenue was $21.25 million, an increase of 1284.50% compared to the previous year's $1.54 million. Losses were -$16.05 million, -32.34% less than in 2022.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for FENC stock is "Strong Buy." The 12-month stock price forecast is $18.0, which is an increase of 92.72% from the latest price.
News
Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2023 Financial Results and Provides Business Update
~ Achieved PEDMARK® Full-Year 2023 Net Product Sales of $21.3 Million, Including $9.7 Million in Net Product Sales in the Fourth Quarter of 2023 ~
Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2023 Financial Results on March 21, 2024
RESEARCH TRIANGLE PARK, N.C., March 19, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Com...
Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand
Agreement pairs Norgine's commercial expertise and leading European footprint with PEDMARQSI® , the first and only approved therapy in the European Union and U.K. for reducing the risk of cisplatin-in...
Fennec Pharmaceuticals Reports Preliminary Unaudited Net Revenue for Fourth Quarter and Full-Year 2023 Results
~ Fourth Quarter 2023 Net Revenues of Approximately $9.2 to $9.7 Million ~ ~ Company Expects to Report 2023 Fourth Quarter and Audited Full-Year Results on or about March 26, 2024 ~ RESEARCH TRIANGLE ...
FDA Issues Reminder of Non-Substitution of PEDMARK® (sodium thiosulfate injection) for Pediatric Patients Receiving Cisplatin
RESEARCH TRIANGLE PARK, N.C., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the U.S....
Fennec Announces Incremental $5 Million Investment from Petrichor
~ Supports Strategic Discussions and Global Launch Activities ~ ~ Extends Access to Additional Undrawn Capital As Needed During Global PEDMARK® Rollout ~ ~ Facilitates Market Expansion into the Adoles...
Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences
RESEARCH TRIANGLE PARK, N.C., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Compa...
Fennec Pharmaceuticals Announces Third Quarter 2023 Financial Results and Provides Business Update
~ PEDMARK ® Net Product Revenue of $6.5 Million, a 96% Increase Compared to Second Quarter ~ ~ Strong Commercial Uptake Underscoring Significant Unmet Medical Need ~ ~ Received Approval in October 202...
Fennec Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 6, 2023
RESEARCH TRIANGLE PARK, N.C., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Comp...
Fennec Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Business Update
~ Growing Physician Awareness and Usage of PEDMARK ® Drove Quarterly Revenue Growth of 98% ~ ~Fennec Expands Leadership Team with the Appointment of Adrian Haigh as Chief Operating Officer ~ ~ Managem...
Fennec Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 3, 2023
RESEARCH TRIANGLE PARK, N.C., July 31, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Comp...
Fennec Announces Results of Annual Meeting
RESEARCH TRIANGLE PARK, N.C., June 12, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy cir...
Fennec Pharmaceuticals Announces European Commission Marketing Authorization for Pedmarqsi™ (sodium thiosulfate) to Reduce the Risk of Hearing Loss in Pediatric Oncology Patients
Pedmarqsi™ is the First and Only Approved Therapy in the European Union for Reducing the Risk of Cisplatin-induced Hearing Loss (Ototoxicity) in Pediatric Patients with Localized, Non-metastatic Solid...
Fennec Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business Update
~ Strong PEDMARK ® Commercial Momentum Building in 2023 with Broad Payor and Medicaid Coverage ~
Fennec Pharmaceuticals to Report First Quarter 2023 Financial Results on May 11, 2023
RESEARCH TRIANGLE PARK, N.C., May 08, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Compa...
Fennec Pharmaceuticals Receives Positive CHMP Opinion for Pedmarqsi™ (sodium thiosulfate) to Reduce the Risk of Hearing Loss in Pediatric Oncology Patients
~ First Therapy Recommended for Approval in the European Union for Reducing the Risk of Cisplatin-induced Hearing Loss (Ototoxicity) in Pediatric Patients with Localized, Non-metastatic Solid Tumors~
Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2022 Financial Results
~ U.S. Commercial Team in Place with PEDMARK ® Launch Off to Solid Start Following FDA Approval of PEDMARK ® in September 2022 ~
Fennec Pharmaceuticals Announces PEDMARK® (sodium thiosulfate injection) Receives Orphan Drug Exclusivity from U.S. FDA
~ PEDMARK® is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic Solid Tumors ~
Fennec Pharmaceuticals Announces Updated NCCN Clinical Practice Guidelines Recommend PEDMARK® (sodium thiosulfate injection) to Reduce the Risk of Cisplatin-Induced Hearing Loss in Pediatric Patients
~ PEDMARK is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-metastatic Solid Tumors ~
Fennec Pharmaceuticals Announces Third Quarter 2022 Financial Results and Provides Business Update
~ In September 2022, FDA Approved PEDMARK ® , the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Me...
Fennec Pharmaceuticals Announces Commercial Availability of PEDMARK® (sodium thiosulfate injection) in the United States
~ PEDMARK is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Cisplatin-Induced Hearing Loss in Pediatric Patients ~
Fennec Pharmaceuticals Announces Second Closing of $20 Million Investment from Petrichor
~ Under the Terms of the Previously Announced Investment Agreement, $5 Million Already Funded Upon Initial Closing, Which Occurred on August 19, 2022, and $20 Million to be Funded Upon FDA Approval of...
Fennec Pharmaceuticals Announces FDA Approval of PEDMARK® (Sodium Thiosulfate Injection)
~ PEDMARK® is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic Solid Tumors ~
Fennec Pharmaceuticals Closes First $5 Million Investment From Petrichor
~ Under the Terms of the Investment Agreement, $5 Million to be Funded on initial closing and $20 Million to be Funded Upon Potential FDA Approval of PEDMARK TM ~
Fennec Pharmaceuticals Announces Second Quarter 2022 Financial Results and Provides Business Update
~ PEDMARK TM FDA Prescription Drug User Fee Act (PDUFA) Target Action Date Set for September 23, 2022 ~